Equities Analysts Set Expectations for CAPR Q2 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Analysts at B. Riley issued their Q2 2025 EPS estimates for Capricor Therapeutics in a note issued to investors on Wednesday, June 25th. B. Riley analyst M. El-Saadi anticipates that the biotechnology company will post earnings of ($0.48) per share for the quarter. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics' Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at $1.37 EPS, FY2027 earnings at ($0.27) EPS, FY2028 earnings at $1.47 EPS and FY2029 earnings at $2.59 EPS.

CAPR has been the subject of a number of other research reports. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, June 24th. Cantor Fitzgerald restated an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Oppenheimer reduced their price target on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research report on Monday, June 23rd. Finally, Roth Capital restated a "buy" rating and set a $31.00 price target on shares of Capricor Therapeutics in a research report on Tuesday, June 17th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $33.75.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $11.15 on Monday. The company has a market capitalization of $509.33 million, a PE ratio of -7.85 and a beta of 0.85. The company has a fifty day moving average of $10.88 and a 200 day moving average of $12.33. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same quarter in the prior year, the firm earned ($0.31) earnings per share.

Institutional Trading of Capricor Therapeutics

Several hedge funds have recently made changes to their positions in CAPR. Summit Investment Advisors Inc. grew its stake in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after buying an additional 1,345 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after buying an additional 2,947 shares during the period. Virtus ETF Advisers LLC purchased a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $68,000. AlphaQuest LLC purchased a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund grew its stake in shares of Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after buying an additional 5,000 shares during the period. Hedge funds and other institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.